Rabies Diagnostics

Rabies Diagnostics

Global Rabies Diagnostics Market to Reach US$2.8 Billion by 2030

The global market for Rabies Diagnostics estimated at US$1.9 Billion in the year 2023, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2023-2030. Fluorescent Antibody Tests (FAT), one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$910.1 Million by the end of the analysis period. Growth in the Immunohistochemical Tests segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$512.7 Million While China is Forecast to Grow at 7.8% CAGR

The Rabies Diagnostics market in the U.S. is estimated at US$512.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$602.3 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Rabies Diagnostics: Ensuring Timely Detection and Prevention of a Deadly Disease

What Are Rabies Diagnostics and Why Are They Critical in Public Health?

Rabies diagnostics refer to the methods and tools used to detect the rabies virus in animals and humans. Timely diagnosis is essential because rabies is nearly always fatal once symptoms appear, but it is preventable with prompt and effective treatment if identified early. Rabies diagnostics play a crucial role in public health by helping prevent outbreaks, guiding treatment decisions, and informing vaccination campaigns. Accurate diagnostic methods also aid veterinarians and wildlife professionals in identifying infected animals, allowing them to implement control measures to protect both human and animal populations. The disease, which is transmitted through saliva from an infected animal bite, affects the central nervous system and can spread to nearly any warm-blooded species, making effective diagnostics vital for controlling and preventing rabies transmission.

Early and precise rabies diagnostics are essential for assessing possible exposure in bite victims. If rabies is suspected, diagnostics help guide the decision to administer post-exposure prophylaxis (PEP), a life-saving vaccine treatment given before symptoms develop. Rabies testing is also crucial in wildlife and domestic animal control, as animals, particularly wild species like bats, raccoons, foxes, and stray dogs, are primary rabies carriers. Through accurate diagnostics, health authorities can implement surveillance programs, identify at-risk areas, and focus preventive efforts on regions with high incidence rates. These actions are critical in maintaining public health and safety, especially in areas where rabies remains endemic.

What Diagnostic Methods Are Commonly Used to Detect Rabies?

The gold standard for rabies diagnosis is the Direct Fluorescent Antibody (DFA) Test, which involves analyzing brain tissue from an animal postmortem. This test uses fluorescently labeled antibodies that bind to rabies virus antigens, allowing for direct visualization under a microscope. The DFA test is highly sensitive and specific, providing results in a short time frame, and remains the primary method for confirming rabies in animals. However, because it requires brain tissue, it is invasive and can only be performed after the animal`s death, limiting its use to suspected cases in animals that have died or been euthanized.

For humans and in situations where non-invasive testing is preferred, several other diagnostic methods are used. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular technique that detects the presence of rabies virus RNA in samples like saliva, skin biopsies, and cerebrospinal fluid. RT-PCR can be performed on living patients, providing a way to detect rabies before death, though it is less sensitive than DFA and can yield false negatives, especially in early stages of infection. Enzyme-Linked Immunosorbent Assay (ELISA) and serological tests are also used to detect rabies antibodies in blood, though they are typically more useful for confirming previous exposure rather than diagnosing active infection. Combined, these methods enable a more comprehensive diagnostic approach, enhancing the ability to detect and respond to rabies in both animals and humans.

How Are Rabies Diagnostics Evolving with New Technology?

Recent advancements in rabies diagnostics focus on improving speed, accessibility, and non-invasive options for early detection. Rapid rabies diagnostic tests, often based on lateral flow assay technology, have been developed to provide quick, on-site testing results without the need for specialized laboratory equipment. These rapid tests are particularly useful in field settings, allowing veterinarians and health professionals to assess suspected cases quickly and implement quarantine or vaccination measures as needed. Although not as precise as the DFA test, these portable diagnostics offer a valuable tool for preliminary screening, especially in rural or resource-limited areas where access to laboratory facilities may be limited.

Innovations in molecular diagnostics, including real-time PCR and next-generation sequencing, are also enhancing rabies detection capabilities. Real-time PCR techniques can quantify viral load in samples, providing more sensitive detection even at lower viral levels, which is beneficial for early diagnosis in humans and animals. Additionally, research is ongoing into developing non-invasive diagnostic methods that use saliva or tears to detect rabies in living animals, which could potentially enable early detection in domestic pets and reduce the need for euthanasia in suspect cases. As diagnostic technology advances, the goal is to create more accessible, reliable, and humane rabies testing methods that improve disease management and prevention across diverse settings.

What Factors Are Driving the Growth in the Rabies Diagnostics Market?

The growth in the rabies diagnostics market is driven by factors such as increasing awareness of rabies prevention, advancements in diagnostic technologies, and the rising demand for accessible diagnostics in high-risk regions. As awareness grows around the dangers of rabies and the importance of early diagnosis, healthcare authorities and veterinary organizations are prioritizing rabies diagnostic testing to control and prevent outbreaks. Furthermore, rapid urbanization in many parts of the world has increased human-wildlife interactions, raising the potential for rabies exposure and the need for widespread diagnostic capabilities.

Technological advancements have also made rabies diagnostics more accessible, with portable rapid tests and molecular testing techniques now available for field and clinical use. These innovations address the challenges of testing in remote areas, particularly in regions of Africa, Asia, and Latin America, where rabies remains endemic. Additionally, government initiatives and collaborations with non-profit organizations to reduce rabies cases globally, such as the World Health Organization’s “Zero by 30” goal to eliminate human deaths from dog-mediated rabies by 2030, have created a supportive environment for rabies diagnostics development and deployment. These combined factors are driving growth in the rabies diagnostics market, supporting efforts to reduce rabies transmission and improve public health outcomes worldwide.

SCOPE OF STUDY:

The report analyzes the Rabies Diagnostics market in terms of US$ Thousand by the following Method; Technology, and Geographic Regions/Countries:

Segments:
Method (Fluorescent Antibody Tests (FAT), Immunohistochemical Tests, Amplification Methods, Histologic Examinations, Serology Tests); Technology (ELISA / Immunohistochemistry, Chromatography, PCR, Other Technologies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbexa Ltd.
• Aviva Systems Biology Corporation
• BioNote, Inc.
• Bio-Rad Laboratories, Inc.
• Creative Diagnostics
• Demeditec Diagnostics GmbH
• Express Biotech International Inc.
• Merck KGaA
• MyBioSource.com
• Norgen Biotek Corp.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.